Alivus Life Q1 FY27 Share Price & Earnings Call Analysis

Financials of Alivus Life

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Alivus Life

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +621578595573537589507642650602588673689
Expenses +415385428400395429373452451430409442475
Operating Profit206193167173141159134190198172179231215
OPM %33%33%28%30%26%27%27%30%31%29%30%34%31%
Other Income +32523591010915-1223
Interest0000000011111
Depreciation12131313151415151617182020
Profit before tax198182159161130150127185191163174198216
Tax %26%26%25%26%24%26%25%26%26%25%25%24%25%
Net Profit +1461351191199811195137142122130150163
EPS in Rs11.9511.059.699.697.999.107.7811.1811.589.9110.6012.2513.25

Financials of Alivus Life

Profit & Loss

Annual income statement trend

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +08861,5371,8852,1232,1612,2832,3872,552
Expenses +06381,0641,2941,5061,5181,6081,7021,755
Operating Profit-0248473592617643675684797
OPM %-4%28%31%31%29%30%30%29%31%
Other Income +0-01101428113335
Interest013488281225
Depreciation01929333842536175
Profit before tax-0228421471565629631654751
Tax %4,200%14%26%25%26%26%25%26%25%
Net Profit +-0196313352419467471486564
EPS in Rs-430.00997.861,597.37358.7434.1738.1138.4339.6345.99
Dividend Payout %0%0%0%0%61%110%59%13%11%

Financials of Alivus Life

Balance Sheet

Capital structure and asset base

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital0.012222525252525
Reserves-1864007512,0302,1142,3082,7933,308
Borrowings +0000319175757
Other Liabilities +11,3871,3241,244414545501537594
Total Liabilities01,4751,7261,9972,4712,7022,8503,4113,983
Fixed Assets +04565465735957818059551,048
CWIP08011149262106102273
Investments0000000478780
Other Assets +09391,1691,4101,7841,8601,9391,8771,881
Total Assets01,4751,7261,9972,4712,7022,8503,4113,983

Financials of Alivus Life

Cash Flows

Operating, investing and financing cash movement

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-010195388598306414392565
Cash from Investing Activity +0-9-51-69-122-147-116-616-570
Cash from Financing Activity +01-137-214-79-388-279-6-64
Net Cash Flow028106397-22818-230-69
Free Cash Flow-01144322466143285226259
CFO/OP4,800%14%61%84%119%71%85%81%93%

Financials of Alivus Life

Ratios

Working capital efficiency and return ratios

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days44185152120116136122148153
Inventory Days162441227214185224251237237
Days Payable4120111192110158139137127
Cash Conversion Cycle165424268241190202235248263
Working Capital Days-2,059-186-3712149176188201306
ROCE %529%186%97%42%30%28%25%25%

Continue your research

What Alivus Life's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • IOL Chemicals (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharma. (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

  • Strides Pharma (Q1 FY27)

    markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divi's Lab.vs Torrent Pharmaceuticals Ltd